Key insights
- Greenwich LifeSciences (GLSI) announced the use of commercially manufactured GP2 in its Phase III FLAMINGO-01 trial at US sites after FDA approval. The company plans to expand this to European, U.K., and Canadian sites. Preliminary data shows a potential 80% reduction in breast cancer recurrence rates in one arm of the trial. While currently unprofitable, analysts have optimistic price targets. This news has a slightly positive influence, reflecting potential future revenue.
STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI) announced that all approximately 40 U.S. clinical sites in its FLAMINGO-01 trial have begun treating patients with commercially manufactured GP2, according to a press release statement. The biotech company, with a market capitalization of $370 million, has seen its stock surge 123% over the past year despite remaining unprofitable.
The company reported that the FDA approved the first commercial lot of GP2 vials for use in the Phase III trial following a recent data submission. The commercial GP2 was manufactured in 2024 at a commercial facility, with the active ingredient produced in 2023.
Greenwich LifeSciences stated it plans to submit the same manufacturing information to European, U.K., and Canadian regulators for approval to use commercially manufactured GP2 at all approximately 160 sites participating in FLAMINGO-01. The company said it is planning to manufacture additional vials, targeting a capacity of 500,000 to 1 million vials per year.
FLAMINGO-01 is evaluating GLSI-100, an immunotherapy designed to prevent breast cancer recurrences. The trial has screened more than 1,000 patients at a current rate of approximately 800 patients per year. The 250-patient non-HLA-A02 arm is fully enrolled.
The company reported preliminary analysis of recurrence rates in the non-HLA-A02 arm shows an approximately 80% reduction in recurrence rate after the Primary Immunization Series is completed. The company noted this preliminary data is not completed or fully reviewed and may differ from final results.An InvestingPro tip notes the company is not profitable over the last twelve months, with EPS of -$1.46. Analysts remain optimistic, setting price targets between $45 and $50, well above the current price of $26.74.
The Phase III trial is designed to enroll approximately 500 HLA-A02 patients randomized to GLSI-100 or placebo, plus up to 250 patients of other HLA types treated with GLSI-100. The trial requires 28 events to detect a hazard ratio of 0.3 in invasive breast cancer-free survival.
CEO Snehal Patel said the company internalized its clinical team in the fourth quarter of 2025.
In other recent news, Greenwich LifeSciences reported a significant development in its FLAMINGO-01 Phase III clinical trial, with patient screening rates increasing by 33% to approximately 800 patients annually. This rise is attributed to the activation of new sites and increased activity at existing locations. Additionally, the company announced that two abstracts have been accepted for presentation at the American Association for Cancer Research Annual Meeting 2026, highlighting ongoing research efforts. Greenwich LifeSciences also revealed a boost in its financial position, raising $7 million in January 2026 through its at-the-market financing vehicle, which more than doubled its cash balance to $12.5 million. The company noted a cash burn rate of $9.5 million in 2025, up from $7 million in previous years. Furthermore, the U.S. Food and Drug Administration approved the use of the first commercial lot of GP2 vials in the FLAMINGO-01 trial, marking a key milestone for the company’s breast cancer recurrence immunotherapy. This approval follows the manufacturing of three commercial lots of GP2, with a capacity to prepare 200,000 doses. These recent developments underscore Greenwich LifeSciences’ progress in both clinical and financial aspects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.